Date of publication: February 02, 2021

Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report is produced to present all currently available evidence considered in the assessment of Pfizer-BioNTech COVID-19 Vaccine. This assessment follows the HTAC evaluation framework to assess COVID-19 vaccines which consists of the following criteria: (1) responsiveness to magnitude and severity; (2) clinical efficacy and safety; (3) affordability and viability; (4) household financial impact; (5) social impact; and (6) responsiveness to equity.

Guidance for General Public: https://hta.doh.gov.ph/2021/02/09/pfizer-biontech-covid-19-vaccine-under-emergency-use-authorization-eua/

Guidance for General Public (Filipino): https://hta.doh.gov.ph/2021/04/14/gabay-sa-publiko-tungkol-sa-pfizer-biontech-covid-19-vaccine/

Guidance for Health Care Provider: https://hta.doh.gov.ph/2021/02/09/pfizer-biontech-covid-19-vaccine/

Guidance for Health Care Provider (Filipino): https://hta.doh.gov.ph/2021/04/14/gabay-sa-mga-health-care-provider-tungkol-sa-pfizer-biontech-covid-19-vaccine/

Evidence summary: Evidence Summary on BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) for the prevention of COVID-19

HTAC Recommendation Preview: